Table 4.
Multivariate survival analysis in classical Hodgkin lymphoma patients
| Variable |
HIV- cHL |
HIV- MC subtype |
HIV- NS subtype |
|||
|---|---|---|---|---|---|---|
| P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | |
| Age ≥50 years |
<0.001 |
6.837 (2.588-18.062) |
0.009 |
15.669 (1.995-123.042) |
0.915 |
0.888 (0.099-7.967) |
| Advanced stage |
0.403 |
1.584 (0.539-4.652) |
0.329 |
2.263 (0.440-11.654) |
0.141 |
3.382 (0.669-17.095) |
| Bulky disease |
0.040 |
3.822 (1.060-13.783) |
0.051 |
5.146 (0.991-26.725) |
0.646 |
1.732 (0.166-18.091) |
| Blood monocyte |
0.111 |
0.906 (0.802-1.023) |
0.100 |
0.860 (0.719-1.029) |
0.009 |
0.640 (0.459-0.894) |
| IDO |
0.111 |
1.018 (0.996-1.040) |
0.378 |
1.011 (0.98601.037) |
0.001 |
1.104 (1.043-1.168) |
| CD163 |
0.812 |
1.002 (0.982-1.023) |
0.439 |
1.008 (0.987-1.030) |
0.020 |
1.061 (1.009-1.116) |
| CD68 | 0.636 | 0.970 (0.854-1.101) | 0.906 | 0.992 (0.872-1.129) | 0.735 | 1.056 (0.772-1.443) |
HR, hazard ratio; CI, confidential interval; HIV, human immunodeficiency virus; cHL, classical Hodgkin lymphoma; HR, hazard ratio; CI, confidential interval; IDO, indoleamine 2,3-dioxygenase.